Render Target: STATIC
Render Timestamp: 2024-12-20T10:59:56.456Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:58:12.565
Product last modified at: 2024-12-17T18:50:33.270Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CELA2A (E1D6G) Rabbit mAb #23050

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 26
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CELA2A (E1D6G) Rabbit mAb recognizes endogenous levels of total CELA2A protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly176 of human CELA2A protein.

    Background

    Chymotrypsin-like elastase family member 2A (CELA2A) was initially described as an exocrine elastase, produced by exocrine cells of the mammalian pancreas (1,2). Deeper examination revealed additional, lower levels of CELA2A expression by a small subset of pancreatic islet cells and many other tissues, including the adrenal glands, intestine and colon, liver, and white adipose tissue (3). Notably, gene expression datasets have reported aberrant CELA2A expression by other tissues in association with specific disease states (e.g., insulin resistance or Type II diabetes) (3), while increased expression of CELA2A by colonic epithelial cells was reported in patients with inflammatory bowel diseases (4). CELA2A is a secreted protease; in normal physiology, it is released into circulation following an elevation in plasma glucose levels, where it promotes both insulin secretion and degradation, leading to increased insulin sensitivity (3). Importantly, mutations in the CELA2A gene were shown to inhibit the ability of CELA2A to regulate insulin dynamics (3). Collectively, these studies suggest that CELA2A may be an attractive therapeutic target in both metabolic and inflammatory diseases.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.